RESUMO
Objective To explore the clinical efficacy and safety of bevacizumab combined with docetaxel in treatment of advanced cervix cancer.Methods Seventy-five patients with advanced cervix cancer accepted in our hospital from April 2011 to April 2016 were selected and divided into observation group with 43 cases and control group with 32 cases according to different treatment methods.Patients in control group were given docetaxel,and patients in observation group were combined with bevacizumab on the basis of control group.The clinical efficacy,adverse reactions,life quality and pharmacoeconomics of two groups were observed and compared.Results The total efficacy and clinical control rate of observation group were all higher than control group with statistically significance (P ＜ 0.05).The adverse reaction rate of two groups had no difference.Total efficacy of life quality improvement was 83.72％,which was obviously higher than control group 62.50％ with statistically significance (P ＜ 0.05).The average cost of observation group was (83 ± 10) thousands,of control group was (18± 6) thousands.The cost of observation group was obviously higher than control group with statistically significance (P ＜ 0.05).Conclusion Using bevacizumab combined with docetaxel in treatment of advanced cervix cancer has better effect clinical but costs much than docetaxel.We should set on treatment according to patients' own situation.
RESUMO
OBJETIVO: Analizar retrospectivamente resultados y factores pronósticos de pacientes con cáncer cérvico uterino estadío IIIB tratados con radio quimioterapia concomitante basado en cisplatino. MÉTODOS: Desde septiembre 1999 a diciembre 2002, 48 pacientes con cáncer cérvico uterino estadío IIIB fueron tratados en el Servicio de Oncología del Hospital Carlos Van Buren. La edad promedio fue 46,7 años. La histología correspondió a carcinoma escamocelular en 89,5% de los casos. El tratamiento consistió en radioterapia pelviana externa y braquiterapia útero-vaginal con baja tasa de dosis (dosis total de 85 Gy a punto A). La quimioterapia concomitante consistió en cisplatino semanal 40 mg/m² con máximo de 70 mg, por 5 semanas. RESULTADOS: 85,4% de las pacientes completó 5 ciclos de quimioterapia. La mediana de sobrevida global fue 39 meses, con una sobrevida global, sobrevida libre de enfermedad y sobrevida libre de recurrencia loco-regional a 3 años de 55,6%, 53,3% y 78,6%, respectivamente. 12,5% de los pacientes recidivó en pelvis y 22,9% desarrollaron metástasis a distancia. No se encontraron factores pronósticos de sobrevida global ni sobrevida libre de enfermedad, observando que diámetro tumoral clínico 7 cm y no realización de braquiterapia fueron factores de mal pronóstico de sobrevida libre de enfermedad loco-regional. CONCLUSIONES: El tratamiento con radioterapia pelviana externa, braquiterapia y quimioterapia concomitante con cisplatino semanal en pacientes con cáncer cérvico uterino estadío IIIB es posible de realizar en el sistema de salud público chileno, con buena tolerancia y resultados comparables a los de la literatura internacional.
OBJECTIVE: With a retrospective study we propose to analyze results and prognostic factors of patients with FIGO stage IIIB cervical carcinoma of the intact uterine cervix treated with cisplatin-based chemotherapy concurrently with standard radiotherapy. METHODS: From September 1999 to December 2002, 48 patients with stage IIIB cervical carcinoma were treated at the department of oncology from Carlos Van Buren Hospital. The mean age was 46.7 years; 89.5% was squamous cell carcinoma. Treatment consisted of radiotherapy (external-beam radiotherapy and low dose rate brachytherapy) plus weekly cisplatin chemotherapy (40 mg/m²) for five weeks. The total dose to point A was 85 Gy. RESULTS: 85.4% received 5 cycles. The median overall survival was 39 months with 3 year overall survival, disease-free survival and loco-regional disease-free survival of 55.6%, 53.3% and 78.6%, respectively. 12.5% had recurrence disease in pelvis and 22.9% developed metastatic disease. We did not find prognostic factors for overall survival and disease-free survival. Prognostic factors related with poor loco-regional disease-free survival were clinical tumor diameter 7 cm and patients who did not have brachytherapy. CONCLUSIONS: The treatment regimen of external pelvic irradiation, brachytherapy and concurrent weekly cisplatin in patients with stage IIIB cervical carcinomas is feasibility to do in the Chilean public health system, with good tolerance and comparable results to the international trials.